Table 2 Study outcomes in case and control group
Outcomes | HIV+TB (Cases: n = 63) | HIV+ (Controls: n = 51) | P value |
|---|---|---|---|
Vital status at 48 week -Weight -Hemoglobin | 1. 53.2 ± 8.65 ii. (12.9 ± 1.01 | 55.7 ± 9.12 12.5 ± 1.52 | 0.32 0.33 |
Mortality | 13 (20.63%) | 4 (7.84%) | 0.068 |
Mean increase in CD4 cell count at 24 weeks from Baseline | 108.3 | 112.7 | 0.83 |
Mean increase in CD4 cell count at 48 weeks from Baseline | 128.2 | 148.4 | 0.69 |
Viral load suppression at 24 Weeks (≤ 400 copies/ml) | 35 (55.5%) | -- | -- |
Viral load suppression at 48 Weeks (≤ 400 copies/ml) | 37 (58.73%) | -- | -- |
Immunological failure | 6 (9.5%) | 2 (3.9%) | 0.313 |
Virological failure | 5 (7.93%) | -- | -- |
Clinical Progression at 48 weeks | 6 (9.5%) | 2 (3.9%) | 0.313 |